Drugs in ATC Class D07AD

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D07 - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Up to D07A - CORTICOSTEROIDS, PLAIN

Drugs in ATC Class: D07AD - Corticosteroids, very potent (group IV)

Tradename	Generic Name
CLOBETASOL PROPIONATE	clobetasol propionate
OLUX	clobetasol propionate
OLUX E	clobetasol propionate
CLOBETASOL PROPIONATE (EMOLLIENT)	clobetasol propionate
CORMAX	clobetasol propionate
EMBELINE E	clobetasol propionate
IMPOYZ	clobetasol propionate

Corticosteroids, Very Potent (Group IV): Market Dynamics and Patent Landscape

Last updated: February 19, 2026

This analysis examines the market and patent landscape for very potent corticosteroids, ATC Class D07AD. Key findings indicate a mature market with established players and a substantial patent portfolio, primarily focused on novel formulations and delivery systems rather than new active pharmaceutical ingredients. Emerging trends suggest continued innovation in topical delivery and combination therapies to address unmet needs in severe inflammatory skin conditions.

What is the Market Size and Growth for Very Potent Corticosteroids (D07AD)?

The global market for topical corticosteroids, including very potent agents, is substantial. While specific data for the D07AD sub-class is limited due to its niche within the broader corticosteroid market, the overall topical corticosteroid market was valued at approximately USD 3.5 billion in 2022 and is projected to reach USD 4.7 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.8% [1]. Very potent corticosteroids represent a significant segment within this market due to their efficacy in treating severe dermatological conditions.

Market growth is driven by:

• Increasing prevalence of inflammatory skin diseases: Conditions such as severe psoriasis, atopic dermatitis, and contact dermatitis, which often require potent corticosteroid treatment, are on the rise globally [2].
• Aging population: Older individuals are more susceptible to chronic inflammatory skin conditions, contributing to sustained demand.
• Advancements in drug delivery systems: Innovations in formulations (e.g., foams, ointments, lotions) enhance patient compliance and therapeutic outcomes, supporting market expansion.
• Geographic expansion and market access: Increased healthcare infrastructure and rising disposable incomes in emerging economies are creating new market opportunities.

However, market growth faces constraints from:

• Side effect concerns: Long-term use of potent corticosteroids can lead to adverse effects like skin thinning, striae, and systemic absorption, prompting a search for alternative therapies.
• Availability of biosimilars and generics: While less prevalent for highly specialized or patented formulations, generic competition can pressure pricing.
• Development of biologic therapies: For severe inflammatory conditions, biologic drugs are gaining traction as alternatives or adjuncts to corticosteroids, potentially moderating growth in the corticosteroid segment [3].

Which are the Leading Very Potent Corticosteroids in the D07AD Class?

The D07AD classification encompasses the most potent topical corticosteroids. Leading active pharmaceutical ingredients (APIs) in this class include:

• Clobetasol Propionate: Widely recognized as a benchmark very potent corticosteroid. It is a synthetic corticosteroid with strong anti-inflammatory, antipruritic, and vasoconstrictive actions [4].
• Betamethasone Dipropionate (high potency formulations): While betamethasone exists in various potencies, specific formulations are categorized within D07AD due to their high efficacy. It is a synthetic corticosteroid with potent anti-inflammatory properties [5].
• Halobetasol Propionate: Another highly potent synthetic corticosteroid used for severe inflammatory skin conditions. Its mechanism involves suppressing the release of inflammatory mediators [6].
• Desoximetasone (high potency formulations): Available in various potencies, certain formulations of desoximetasone exhibit very high potency and are classified under D07AD. It has strong anti-inflammatory and vasoconstrictive effects [7].

These APIs are formulated into various topical preparations, including ointments, creams, lotions, solutions, and foams, to cater to different skin types and disease presentations.

What is the Current Patent Landscape for Very Potent Corticosteroids?

The patent landscape for very potent corticosteroids is characterized by a mature base of active ingredients with expired or soon-to-expire composition of matter patents. Innovation has shifted towards formulation technologies, delivery systems, and combination products.

Key patenting trends include:

• Novel Formulations: Patents are frequently filed for improved formulations that enhance skin penetration, stability, patient compliance, and reduce side effects. Examples include:
  • Foam formulations: These offer better spreadability and a non-greasy feel, improving adherence, particularly on hairy areas [8].
  • Liposomal or nano-emulsion delivery systems: These technologies aim to improve drug targeting, efficacy, and reduce systemic absorption [9].
  • Combination products: Patents often cover combinations of a potent corticosteroid with other active ingredients, such as salicylic acid for enhanced efficacy in conditions like psoriasis, or antifungals/antibacterials for mixed infections [10].
• Delivery Devices: While less common for standard topical applications, patents may cover specialized application devices for enhanced targeted delivery or ease of use.
• Manufacturing Processes: Patents may also protect novel or improved methods of synthesizing the corticosteroid API or manufacturing specific complex formulations, aiming for higher purity or yield.
• Therapeutic Uses and Dosing Regimens: Patents can be secured for new indications of existing potent corticosteroids or for specific, optimized dosing schedules that demonstrate improved efficacy or reduced adverse effects in certain patient populations.

Major patent holders often include:

• Large pharmaceutical companies: Companies with established dermatology portfolios hold significant patent assets.
• Specialty dermatology companies: Firms focused specifically on dermatological treatments are active in patenting novel formulations.
• Academic institutions: Research from universities can lead to foundational patents on new delivery technologies.

The expiration of foundational patents for APIs like clobetasol propionate has opened the door for generic manufacturers, but innovation in formulation continues to provide differentiation and patent protection for brand-name products.

What are the Key Patent Expirations and Their Impact?

The expiration of primary composition of matter patents for the core D07AD APIs has had a significant impact:

• Increased Generic Competition: For APIs where primary patents have expired, generic versions have entered the market. This leads to price erosion and increased accessibility. For example, clobetasol propionate, a long-established potent corticosteroid, faces substantial generic competition [11].
• Shift to Life Cycle Management: Pharmaceutical companies have responded by focusing on developing and patenting improved formulations and delivery systems for their existing APIs. This strategy aims to extend market exclusivity and differentiate their products from generics [9]. Examples include patents covering specific vehicle compositions, particle sizes, or delivery devices that enhance the performance of the corticosteroid.
• Focus on Combination Products: The patenting of combination products, where a potent corticosteroid is combined with another therapeutic agent, represents a strategy to create novel entities with distinct patent protection. These products can offer synergistic benefits and address complex dermatological conditions more effectively [10].
• Innovation in Drug Delivery: Companies are investing in research and development for advanced drug delivery technologies. Patents related to liposomes, nanoparticles, transdermal patches, and novel topical vehicles aim to improve the pharmacokinetic and pharmacodynamic profiles of potent corticosteroids, offering new avenues for patent protection and market exclusivity.

The expiration of foundational patents does not signal an end to innovation but rather a strategic pivot towards post-patent strategies.

What are the R&D Trends and Future Outlook for Very Potent Corticosteroids?

Research and development in the D07AD class are focused on enhancing the therapeutic profile of existing potent corticosteroids and addressing the limitations associated with their use.

Current R&D trends include:

• Enhanced Topical Delivery Systems:
  • Nanotechnology-based formulations: Development of nanocarriers (e.g., liposomes, solid lipid nanoparticles, polymeric nanoparticles) to improve skin penetration, target drug delivery to specific skin layers, and potentially reduce systemic absorption and local side effects [9].
  • Advanced vehicle technologies: Research into novel creams, ointments, gels, and foams that optimize drug release, stability, and cosmetic acceptability. This includes formulations designed for specific skin conditions or body sites.
• Combination Therapies:
  • Corticosteroid + Vitamin D Analogues: Combining potent corticosteroids with vitamin D analogues (e.g., calcipotriol) is a well-established strategy for psoriasis treatment, offering synergistic effects and potentially allowing for lower corticosteroid doses [10]. Ongoing research may explore novel ratios or delivery methods for such combinations.
  • Corticosteroid + Keratolytics: Combining potent corticosteroids with agents like salicylic acid or urea to enhance penetration and stratum corneum removal, particularly beneficial for hyperkeratotic lesions in psoriasis or ichthyosis [10].
  • Corticosteroid + Antimicrobials/Antifungals: Developing fixed-dose combinations to treat inflammatory conditions that are also complicated by secondary infections.
• Minimizing Side Effects:
  • Prodrug strategies: Designing prodrugs that are activated locally in the skin, reducing systemic exposure.
  • Targeted delivery: Formulations or devices that direct the corticosteroid to the affected epidermal or dermal layers, sparing healthy adjacent skin.
• Exploration of New Indications: While the core indications are well-defined, research may explore the efficacy of existing potent corticosteroids in less common or severe dermatological conditions under specific circumstances, often supported by new formulation advancements.
• Biologics and Novel Non-Corticosteroid Treatments: The significant rise of biologic therapies (e.g., IL-17 inhibitors, IL-23 inhibitors, JAK inhibitors) for severe inflammatory dermatoses presents a competitive landscape [3]. R&D efforts in corticosteroids may focus on their role as initial treatment, adjunct therapy, or for patients who do not respond to or tolerate biologics.

Future Outlook:

The future of D07AD corticosteroids will likely involve a continued emphasis on sophisticated formulation science and strategic combinations. While the discovery of entirely new potent corticosteroid molecules is improbable due to the maturity of the field and significant safety concerns, optimizing the delivery and therapeutic index of existing compounds remains a priority. The market will likely see a bifurcation:

1. Commoditized generics: For basic formulations of APIs with expired patents.
2. Differentiated branded products: Leveraging patented novel formulations, delivery systems, and combination therapies that offer improved efficacy, safety profiles, or patient convenience.

The competitive pressure from biologics will drive innovation in topical corticosteroids towards more targeted, effective, and well-tolerated options to maintain their relevance in managing severe inflammatory skin diseases.

Key Takeaways

• The global topical corticosteroid market, including very potent agents (D07AD), is substantial and growing, driven by the rising prevalence of inflammatory skin diseases.
• Leading APIs in the D07AD class include clobetasol propionate, betamethasone dipropionate (high potency), halobetasol propionate, and desoximetasone (high potency).
• The patent landscape is dominated by formulations, delivery systems, and combination products, as composition of matter patents for older APIs have largely expired.
• Patent expirations have led to increased generic competition, prompting pharmaceutical companies to focus on life cycle management through innovative formulations and combination therapies.
• Future R&D trends prioritize nanotechnology-based delivery, advanced vehicle technologies, and combination products to enhance efficacy and minimize side effects, positioning potent corticosteroids as vital, albeit evolving, treatment options.

Frequently Asked Questions

1. Are there any new chemical entities (NCEs) for very potent corticosteroids currently in late-stage development? No significant late-stage clinical development pipelines are publicly disclosed for entirely new chemical entities within the D07AD classification. Innovation is primarily focused on improving existing APIs through novel formulations and delivery methods.

2. What is the typical duration of patent protection for new formulations of potent corticosteroids? New formulations typically receive patent protection for 20 years from the filing date, with potential for patent term extensions in certain jurisdictions to compensate for regulatory review delays. This provides a window for market exclusivity.

3. How does the cost of branded D07AD products compare to their generic equivalents? Branded products leveraging patented formulations or delivery systems are generally priced significantly higher than generic equivalents of the same API, reflecting the innovation and extended market exclusivity they provide.

4. What are the primary safety concerns associated with long-term use of D07AD corticosteroids, and how is R&D addressing them? Primary safety concerns include skin atrophy, striae, telangiectasias, hypothalamic-pituitary-adrenal (HPA) axis suppression, and Cushing's syndrome. R&D addresses these through enhanced delivery systems (e.g., nanotechnology, targeted release) to minimize systemic absorption, and through combination therapies that may allow for reduced corticosteroid dosages.

5. What role do D07AD corticosteroids play in the treatment paradigm alongside emerging biologic therapies? Very potent corticosteroids often serve as first-line therapy for severe flares of inflammatory skin diseases, or as adjunct therapy to biologics. They are also critical for patients who are not candidates for or have failed biologic therapies, or for rapid symptomatic relief. Their role is evolving to complement, rather than be entirely replaced by, advanced systemic treatments.

Citations

[1] Grand View Research. (2023). Topical Corticosteroids Market Size, Share & Trends Analysis Report By Product (Low, Medium, High, Very High Potency), By Formulation (Creams, Ointments, Lotions, Gels, Foams), By Application (Psoriasis, Dermatitis, Eczema, Acne), By Distribution Channel, By Region, And Segment Forecasts, 2023-2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/topical-corticosteroids-market

[2] National Eczema Association. (n.d.). Eczema Statistics. Retrieved from https://nationaleczema.org/eczema-statistics/

[3] Global Initiative for Asthma (GINA). (2023). Global Strategy for Asthma Management and Prevention. Retrieved from https://ginasthma.org/

[4] Fiviz. (n.d.). Clobetasol Propionate. Retrieved from https://www.fiviz.com/drugs/clobetasol-propionate

[5] MedlinePlus. (2023). Betamethasone Topical. Retrieved from https://medlineplus.gov/druginfo/meds/a682016.html

[6] Drugs.com. (2023). Halobetasol Topical. Retrieved from https://www.drugs.com/mtm/halobetasol-topical.html

[7] RxList. (2023). Desoximetasone. Retrieved from https://www.rxlist.com/desoximetasone-topical-drug.htm

[8] Public Library of Science (PLOS). (2017). Foam Formulations for Topical Drug Delivery. Pharmaceutical Research, 34(11), 2206–2221.

[9] ScienceDirect. (n.d.). Nanotechnology in Topical Drug Delivery. Advanced Drug Delivery Reviews, Volume 159.

[10] American Academy of Dermatology Association. (n.d.). Psoriasis: Diagnosis and Treatment. Retrieved from https://www.aad.org/public/diseases/psoriasis/treatment

[11] U.S. Food and Drug Administration (FDA). (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book